-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PlvjDsO6hfLQX/JDBMYaJKVOK0XpJyiyacPg4F907QFYU6BelJrhyl5RoJjz38P6
 wm2/aR7LuAF9C71yNvX3ZQ==

<SEC-DOCUMENT>0000950123-10-013426.txt : 20100216
<SEC-HEADER>0000950123-10-013426.hdr.sgml : 20100215
<ACCEPTANCE-DATETIME>20100216172620
ACCESSION NUMBER:		0000950123-10-013426
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100216
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100216
DATE AS OF CHANGE:		20100216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		10609952

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a55240e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Date of Report (Date of earliest event reported): February&nbsp;16, 2010</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>LifeVantage Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Colorado</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-30489</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>90-0224471</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other <BR>
Jurisdiction of <BR>
Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>11545 W. Bernardo Court, Suite&nbsp;301, San</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Diego, California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>92127</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
Registrant&#146;s telephone number, including area code: <B>(858)&nbsp;312-8000</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>(Former name or former address if changed since last report.)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</TD>
</TR>
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link2 "Item&nbsp;2.02 Results of Operations and Financial Conditions" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.02</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Results of Operations and Financial Conditions</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;16, 2010, Lifevantage Corporation issued a press release announcing its unaudited
second quarter fiscal 2010 financial and operating results. The press release is furnished as
Exhibit&nbsp;99.1 hereto and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing.
</DIV>
<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt"><DIV style="margin-left:0px; text-indent:-0px">Press release dated February&nbsp;16, 2010.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 " SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">Dated: February 16, 2010        &nbsp;</TD>
    <TD colspan="3" align="left">L<FONT style="font-variant: SMALL-CAPS"><B>ifeVantage Corporation</B></FONT><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">                              /s/ Carrie E. Carlander
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Carrie E. Carlander&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer, Secretary &#038; Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a55240exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a55240a5524000.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIFEVANTAGE ANNOUNCES UNAUDITED SECOND QUARTER FISCAL 2010 FINANCIAL AND OPERATING RESULTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Company Records Increase of Over 30% in Net Revenue Over First Fiscal Quarter 2010</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Conference call scheduled for March&nbsp;2, 2010 at 1:30pm (Pacific); simultaneous webcast at</B><BR>
<U><B>www.lifevantage.com</B></U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>San
Diego</B>, <B>CA, February&nbsp;16, 2010</B>, <U>LifeVantage Corporation (OTCBB: LFVN),</U> the maker of
science-based solutions to oxidative stress, announced today unaudited second quarter fiscal 2010
financial and operating results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company recorded an increase of over 30% in net revenue over the first fiscal quarter of 2010,
or approximately $2.5&nbsp;million for the three month period ended December&nbsp;31, 2009. For the three
month period ended December&nbsp;30, 2008, the Company recorded net revenue of approximately $578,000.
The continued growth in revenue is due to the Company&#146;s on-going expansion into the network
marketing distribution model. The company also recorded approximately $2,044,000 of gross profit,
maintaining its 83% gross margin from the first fiscal quarter 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Total operating expenses for the three months ended December&nbsp;31, 2009 were approximately $4.7
million as compared to operating expenses of approximately $4.6&nbsp;million for the three months ended
September&nbsp;30, 2009. This slight increase is primarily attributable to the final settlement of the
Zrii LLC litigation totaling $400,000, as well as anticipated increases in distributor compensation
associated with increases in net revenue over the fiscal quarter, offset by approximately $530,000
of net reductions in sales and marketing, and general and administrative expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company recorded a net loss for the three months ended December&nbsp;31, 2009 of approximately
$681,000, or $0.01 per share, which included other income of approximately $1,999,000, primarily as
the result of the change in fair value of the derivative warrant liability during the three months
ended December&nbsp;31, 2009 of approximately $2,741,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conference Call Information</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company will hold a conference call on March&nbsp;2, 2010 at 1:30pm Pacific time (4:30pm Eastern
time) to discuss second fiscal quarter 2010 financial and operating results and provide an update
on its business. David W. Brown, President &#038; Chief Executive Officer, is scheduled to lead the call
and will be joined by Carrie E. Carlander, Chief Financial Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The conference call may be accessed by dialing 800-580-4832 for domestic callers and entering the
pass code 5852482. The webcast will be available live via the Internet by accessing the Investors
section of LifeVantage&#146;s website at <U>http://www.lifevantage.com/investor-profile.aspx.</U>
Replays of the webcast will be available on LifeVantage&#146;s website for 30&nbsp;days and a phone replay
will be available through March 7<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>, 2010 by dialing 888-203-1112 and entering the pass
code 5852482.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About LifeVantage Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, nutraceutical company
dedicated to helping people reach their health and wellness goals. Founded in 2003 and based in San
Diego, CA, LifeVantage develops products, including Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, that are intended to
deliver significant health benefits to consumers. For more information, visit
<U>www.LifeVantage.com.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as words such as &#147;believe,&#148; &#147;hopes,&#148;
&#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148; &#147;anticipates&#148; and variations thereof,
identify forward-looking statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of performance and the
Company&#146;s actual results could differ materially from those contained in such statements. These
forward-looking statements are based on the Company&#146;s current expectations and beliefs concerning
future events affecting the Company and involve known and unknown risks and uncertainties that may
cause the Company&#146;s actual results or outcomes to be materially different from those anticipated
and discussed herein. These risks and uncertainties include, among others, the potential failure or
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a55240a5524000.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">unintended negative consequences of the implementation of the Company&#146;s network marketing sales
channel; the Company&#146;s ability to retain independent distributors or to attract new independent
distributors on an ongoing basis; the potential for third party and governmental actions involving
the Company&#146;s network marketing sales channel; the potential for product liability claims against
the Company; the risk that government regulators and regulations could adversely affect the
Company&#146;s business; future laws or regulations may hinder or prohibit the production or sale of the
Company&#146;s existing product and any future products; unfavorable publicity could materially hurt the
Company&#146;s business; and the Company&#146;s ability to protect its intellectual property rights and the
value of its product. These and other risk factors are discussed in greater detail in the
Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk
Factors&#148;, and in other documents filed by the Company from time to time with the Securities and
Exchange Commission. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this document. All forward-looking statements are based on
information currently available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect events or circumstances
after the date of this document, except as required by law.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>###</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Investor Relations Contact:</B><BR>
Ioana C. Hone<BR>
(858)&nbsp;312-8000 Ext. 4

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a55240a5524000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a55240a5524000.gif
M1TE&.#EAT@`K`.8``.7IZ>OS]`41,7F%E/7Z^LO4V).<J#M&6Y>BK-/8V[C$
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M]\[AZNKO\<+2VKN]NO+Z^[C`PN[M[L##POK]\MC>X+##TOG\_=_N\SU!3@P4
M)B,O3OO]_7Z`A1L?+;^^Q_#P\9ZNO*RMM.':Y/[^_O[______R'Y!```````
M+`````#2`"L```?_@'^"?WZ%AGZ#@H:"%14X.'\N&!!55#$4-0<V`@):0A-Q
M$'5'I'T0$'V)?Z9UK:>GC8BJLX-^K[<0AX<02DJMLXW!C7U]AL1]1RZW+L6Z
MA;BWM-+3?]"GKJI^=;V^=<^WAXF[J,Z%C(Z0*$=P!&D*(E.;G)PI.Z*D1Z:H
MQ\77KJ^Q")731<B:05&]6ODY)JQ1DR852+W"UR,(!#-K(-#0=Q`:L4/"#AW+
M]@U:*R,+/_+BYLM:N%K&/I8T]Z?1HT805!#X,<#$'$Y:Y@GA<0]?'0@HDO;(
MY^\HP`J(!A*TU1'7MFXI^PC#@0[%THFD;@2YL&</G"!']O%;RZ^"S$(-_V,V
M%,;/:JZU_O"EM9:*5LEHJAHEQ0`G308G/SMI62S`QH^B^"`4\5"D1P^.I^`&
M*P=3ZCB3";T=.](CZ:-'7BN`)?4@`8@)!#1`F!O,;V8_M*$NG)VT=V]QAD0=
MU;OW%"G+_:#1!'ZK51V!*0474:$!2(TH0`4(H4-'R!1[H_1*IER95"M2<V]K
MWER2+3'B1D,/0W:D]^DB16X(-^HC@@D30,!11VX$XF+33:J]<H-OON5V1!T8
MW"#AA&%-B!Q5N"PRRS?.07=*7RA0`4<<7##6V``*H$$$$7DD.%L%6611F65+
ME8:"!Q[$B.`KN/W!H$!/S<5@@[6YU0PT*.0G7/\NHOA0@@02=%!%"$/:=]II
M*!AX)4X*#HG?(SB&Z8%2/>!GIE<TEEE$!3!]^.%'M7'8"I>N](%"!77`P<`(
M06G'!!)CC-%$%E_<TDB,^-%X0VF3Y9@%@DZ]B&92=+XHI&6]83H7,:\XUTJ2
M&+2B1*<P*`!E&AU0624*5Z*&PC^S;9F@<UX6P:J8.-IJF9GXH6DC?O,EUT<:
M<(2@A&RALBEG'2BXH((2!(00+3$AP'$&GYR8,,`8!(#1Q$W"A1!"'2T08"X!
M5(2@`@8H8(%%C%)4P(X/HJBP8))W-A+$`P^HX%RGSCV`P8-U4(>!K;:B$$0?
MVVQ3115P]%*!#C,\VXW_"E4X&84$0,A`!808N'4$!D$,/'!$?=PP0[&^%*/5
M,+84/&X=&HBKP8`5S%"!K3JPJD.8."39B,X8J-`'!ND.Z((.:PJS10<!F`'`
MP$<H2Y5S1;@0\1,QQ`##&@]42X$3?291`Q`$2`%&#EQ](4,(4_H```,,%%``
M"S#`41^.,=[I\0,0!K$@KW?>@,'AHF#0+T(A0!`Q%8"KX,,,"`MVBA)43%G%
MVTJX,,,#$;-<+`Q/2K`%JAH4=U[1&)BBP@-':$"`@!H<?L,QPBD!Q^[G5J%$
M%2I`(+`5P.)01(PY?I'#%TT$,8,HO%2KA!0ZN)#DFBA@8``"!ABP0AY'L0F5
M_S\8>.#"`P!T[ST:>4`\=I]",&%!&!F\@`8,&OA@+`<);%"#"%P0P14&H(<S
M7(`*,Y#"#&;0`C,P(`[1HD[5KE>9:N3D`FY@`0<Z$*T./.$'$6"#`M00`3=X
M;08].!^>'```-XPA#3*`@1LB\(*RH*$``$C5E$:G@"B8H`!TRV`&S1`M=1$`
M!@%X0@'8P$0V).`"^%/<P!BF@F>QXP(,4,`&/K`!!20@!E5T``O=8(86-`$%
M:IN!#QQ@A@2@H88?H``2-C@#%]S`#TO+F@N2,(4II``$+"#`@`;!D3I0!@84
M.$`*4C"%$_S`=^\+BA;H`(5*.F$"3\A?'0"0@0$X(?\)GA#"=@X@@@^X`08J
M@($/.D"!`2#`#1"#`RJ$EA1;:,`,:CB!`7X`A!@4P'\#`$$7NO`:,:R@`&:X
M`0T>L$PWK,`.,>@``%XPA`DL0`YR`$$#B$`!,\A`!E,:@P),8`,QD,`.YR1!
M#;HI@S0$P`UJ0,`)&@"">H*`!$1@`PO@T*^C:$`%XC)#`1!PA2XXX0"7%`,"
M"G`!#Z[@!!2`P;'$)8,`%.`#)`#!->4P@0%8@`<$@$"$4*`#*<AH#BB=@P0*
MT`$5&*$1J^@491SP@I3.H0%N4`$<WJ<826;K![L#P`JZ@)UYF$@(3JC!*<TU
MA@],(0D(N%D51H'&WHB"``G_($$*&L"#"RB`!`O8F`1,D`(30&D*8LC`&JKH
M`QA$``02P.(*%D#61:9``G=(@0@R$`"XP8%T49B#6:$$I05\``!40&0-0'!7
M*/T'KR:8`!&F9K(I$>`):B"!'*+@PR24]3\BL,`3D#"!%*P@`'#0216\:H<%
MC#4%<F@L%!#``%4^H`)2*`)7YM&8!(#3&U:#A0=T$(`,\!8$;M`=!18`E#[-
M(PH[`$(`G&I4`23&N4EP9+HZ$($#W&$",BC,L>HP@R!((0C;",`+%C"'$VR!
M`0V8PQU,0,HA#($$I;W#'4;P`C-0H0/BE,,<&#`$.=QA`78PP!Z((`(#WZ$+
M9^@`_Q426X(H['<!(\#P`B;P@H9>P`YXE0!'[7"">3K8M'FXV2JK\(0/P%4"
M!VC`";@G`B<$]@`6V-,=#!`#&1"@`QS(``CT>X`3K&`#")@`.84P@`(`H0HB
M95<%>&N#!(@+N$`ZQ7"+>UPW%&RYG3`J8Y+`@^D*^+I"2$(2A&`BP7X@#2&0
MP19.<(<HQ*`*!!CO>>_$"S><`*\,Z``22#""$Q3@:02000=\68,4[/<%+:""
M.!=PAT:G@`BGU)OL&'`"$]QA"`D@`!!(9X+OH$H&&HBA[PC``00T8`AX>`(,
MTO"P#NS@`P:6PPOR@(&;!6"N>:T!+]N9ABWP0`$CL,$!//]I`P1$LPKN&'(*
M3E"&"5.!`&/@`1?F8(,AL&!F>:1R`=(PN]EDN0(>D$(,%,#;+B17!<O]R6*2
M,,QZDF"T$T`I)^C`!"*\(`P&8`(=YO'=!/R7"FIPM`5ZW`T)$:,.,%`#7$%@
MACKX(`$4`(`/V"&N8EW<#BE(P@#BT($X6.``<V`D"=S@`Q4$@09`@-H9Q!"%
M!:Q@##(0)Y2V,&$?T,`5(PL"'R*0@#SP*WAU``('`(``2HN`Y0^H0@8F(($I
M[/)C=7A`!RVJU11$H=G1;(T(JHYI5%;Q`;)3P`24K8<#AB`(<'>N$,8M@U$%
M=S;I7G>[&0"W>'-""%<(0QC8H`;_"K38)S]A\AM8L(8+L"`,`N=$RO?@XSJX
M8<@#>$+=LTZR4*G@`@@H*P)`)SD?T(PZ-*.9!AS`A@9$`<*+#@/*[R"""(P!
M#AB@`0TZH'23C\`$=CB@.,W*@2F5[`85HH$5\K`$Y"/_"`]0>@?<4(,[R"$"
M#GC`$TA`U@$$.B(C$U`O6-D`O.[X@`Y8@1Q,L'("5.&?1[@!X,RP@0,(000%
MF%T=;E`!$]F@`%30`B.5+X*Q9>PV#Q/``-3!4P)`!S6P!4"06!V0`$P@#P(`
M83P7:9:@!WR"4G<@!EOP-GDP!%'@!!%E+`+S`"T0`FF051(P`@6``A43*@4#
M.Q!2,#H%_P`UP$<O4&PE@!@2L`$.("+[=P.RTP'3)P82D(`$$``E8%9`$`(M
MT`=P%W^"$R'Q1PJ3H!.\UP$P<`9F]0$70`!JX%H-$`$=T`+_("I*$`(P\`$C
M(%\&8`8AX`9C!P)L($@A<#B-`#A*<`$D$`6Z]C8'@P/.)0$),"!I8B/&,URL
MUUP3X`:R%$D"8`(UT`%*@`)6H`(*,'!!T6Q;@"Y?T`(KR`*=EAA04`;@M`1X
M8'\&<`&<4P<4!03K)0$#8`;NLC,J<`1P5P'9\RIU4`4=$`9.0`<(P&H_.`<@
MD``:D#TXLR@I=`$K$`4'4`+N5#I```$OU8O9PW_(=PV]@&<2YO\Q<9!L-<`#
M0$`$_\%C9$"#,>,<D;8#=&8#!I`',J``KC4$?54!8"`KC;`'!D8$,"`#8.`%
M'F`B=Y"($)`FOD$&CL@&D"B)$$")EHB))/4`>B!)6C`%;_!-'3"*UY8&81"'
MG,"1XM('?'`%`L`%2$`L1R&+,G`!C28'']`!6*`#.^,#1[=`"\0OHD8!3!`%
M0P!@R6@'`(`4Z.6++N`"E@$#%L!(%I`&#H"-1O!2=Y(]%2`6DU`O/M"52,1!
MK+9V5\``6S!V"Y`!,J`VK<`*\)AT&T!.+`($>I`""[`!5*`!8.`#OO$(AU,`
M0R8&%Y`&!7F0??)_24,?:>$<./*(BA'_B9-(-D%AB1)E&0$P!$;%!&>0!AS`
M`4``!%NP!1QP!MMF771@`+W0!TM0`G.0!`K``74G"E30@E2'4Z,R87'V7F>P
M12NP`A^0`06P`R40E"0@71F`<FC@`(U@-'\@!4NP!#30`P_075!UC5`"!)_B
M`3AP7D?0ADH@`T`0!P7P`KS)FQD0`4A0!A6(F3LP9"*0`&`@!5)`"I2"#HU`
M!0S@!#;`(C%0`T+`!8&6!K8I+G'V33(0!V)`!UW``((9(_X'@.."F,)A2![`
MF(OAF!,)F95X`C"``3UP`Q?0`$9U`%<P!'9@7_958F*`&-9E`R+@ACV``7%`
M!Y7V`U("`125_W!R@`!CT#AU0``74`(#L`!WI5_Z)0%T68Q""37%.0<)X`,A
MHYPHH'LIY`-C,YU369USH@,]$P2DJ`$P4`!$,`%R8'YWX%@;E@0L6@!(X%IV
MP`()!'[S>1-2T`$_T`7TF`<[,``L>@8\P`-(\`-($*B"R@-E4`970`<'4``$
M:9"+\8F*.B[B8000@D84*@`62I$GP`&I<P0`T`5&E6:?]1\FH&;=,0\VP`72
MDA8=T`#?10%1F!-5$``&L(04@"X^]@,(T`5E-04C8$_7M$@F($I#(%W(-@<L
M%S(/``$U\9Q3NEQ0!341@*5*D`5>D`,HH`$3=@$?T`#K1Y?VI%&[:O\#<\`%
M:LJF@:0SI4$9CD`I<UJG=_H#5Z!L5R`&`B0&]GJO]\IL27`&!*D#A@@_^6<L
M$%`*MM`$+X4!E1J)LD&)=)"I>@,!```"V2%Y^L9;%GNJ4_('-T`%'Q`%IG4!
MHR(N"=``)C`$3R`N'O0!"V`#4\`%)\!%+U!#!C`$(M`%=&`#=L`!`5"L;M`!
M`P([5>.<I$$`SHH`:3`&V+@-6>`!UBJ+;J5D?Z10&U`_XGD"`)0$<\`$Y7H'
M)'"N7M$HK4(&!(`$=EJ//'`%GD"J4:!F;-NV4R`$+'L&!!`$:]*@;Q,>R*<5
MWS(RC,D)"GNAC&&)6S`N&```$Y`=6F`#^F7_`W!K`X[[N(YK`B(0+3M#!4@P
M`A(@!@P@?CZP7G79`1K@I6IW!P=0`P40!Q#X-C+``4_``!8`!5%``CJK`(C!
M<LH*..S2G/G0`A&P`-,Y!M'*,;U`!H3R*AKP`S50=23P49W9F4"&16>P=N3Z
M`T/6```H@&5"&5<"$3)0`/@YAV=K`W3@!%TP`DXP`NB;ONH+!2-P!4@@`T%P
M)V'66U2@!`,#C4D1(WG2MY;J!@N+H0[(`7NH`FL`HO-`2>6KONA;2>P[`A.`
M``[0`CC@`1K0`<GK!&I`+'```"0H`@S0`F30!&8P!%"R`C'@AD[Q(-JH!&<;
M!3F[LRCG!K=5`49C_U[-V0,5P+N^BP`RX`#!"P3#FR-D@*UH`%<BX*IID,3B
MLD&AFP9ZJK4QP*IG*25ZHR8.T01J"`0;<+-SR`!C)P)G$`-;<`%D?`%F8`9E
M7,8`8`;!XSQ!X'\&9[_QARDHH+]PP+]_2XEFPP%4H#AY0`*\=05GH'2=R9F=
M.08<,`9*QP$A!0&/$&D,L%D&\`0$\``40'4(``02#`8L,&1=T&/2\SKH)0HA
MP`!<()1*5P(Q?%LE<S050",N0`#=95I2^</#FP/PJ0$!T&ERD`$<@"IP%F?B
M@F=`(`:GZEO):P)$$`=311K`4@$/42[RR+@(8`9Q4`,V0`)Q`*#BPA*>\O^2
MT.(O;")W"9#$$',S--@*<%`%#J`&V1&),X`!#-BP@\LPOZ8%B7$`;^"9,N`<
M<;8YLU/)2#$96(`"7Q`#)"`!73!NLFH"<I!_(/P%!3"F1$`L$#`#.K"T.F`1
MLG@&3"`$=N"9)1"';A!2*(`,P2`A1T`%O3L%"."&%``E2-@!.4`QVP``";V,
MB29(34`&.A!2_B(#7/!=!1`$R_5@"H`VNG,SO2`MZ:('!]`8<[@%"/"":N!C
MT5*_@I%;MC(#=\(TN!4$\_M_I]8-WQQG[<Q;D2@P/]@G`4P%#T*&@?6)-1`'
M`@Q]H!,"TE0`"=`"-[`T-X*=8``$*S`%NC9]"3W_`0`@A80RT1*P`B$0`.4U
M7#DR"4H0`&$`!=G,`3&PI($T&\B0"LJ$?+(LI`80`CH7)8G6C^4B`T\@`G>`
M4U3P3=",`^WH.'40`R-P!UH;`MM'5F+PJ*F%,<4B+A$P`3<K!`AP`4"0`;%%
M!`&@:'"@`7``!F"@I9117KZHI9(P9?!S!I_YF9LYWIL9`,3990+#L)=(!<X3
M`@D0AWT"!6]P9^6"+D"`!!]@!T002`\@"5*0)%(@`Q'0!988!R_`6#4``Q"2
M!6#```<@`:<=`*:GI7>",53P!`9PL]#4V2CWV2*3"C1`-2K0NREPVL!;G7'F
M3^8"`&,7B=)"`-NM#/VB_P(%X&E<P(PP\`(3X+$GD``P`#SM\&.X1`)3<`#=
M\8H=4`"S.6X=\#;7ED#P*8,PX`!>33%!\`=AY@D&8`%<WN5>;@$*P``!X,[S
M@%S^,L]G@T`5DSX2(!17H``_8`:(_`1GD*LFL``&``#`XR]U4#(M``"=Q@68
MD`(CP`:M$#)-<+FT9P:I@D#HU:-'2P$E$@4G$`,P?`<E#=KY\`<T<`-_<`3P
MM@!3`-E?:E8[$)MW*3M5$`,@!@(1T'*WI8F;V'+IHU\W?C-,AY^-1`$L(.<Q
M@`2Y"0)R,`(#X(J!^02\3`1/$'-)G#0:T`)!```E$`%'Z3D;82+:80.)"[F0
M>_\`"!``%&!4:RW/9+-O)["/DR`#I(7/0.$$0[`!):``28:U*"4':.`+"EX'
MQ1",^-A(!$X"`$!>.E,'KSU??*4"`2`;7`@##'"H`B`!-<"9JCP''A[:-4$,
M\D?BD$T`;J!PW.(`LT-K`4`$954#+*!3AT-2(.\`1,!><S`!!;`N&/`#!K#;
M-C`"QI0!%E!-CC8"!00%RAW=0'#<I/L!3]`!2?Q-O2`W*^#`;(`!Y14AU66Q
M5"\`*:"C9Z#6+)`*#"B9`\(51C`&0*EO%=NHO#4'"W#5__5-$$(,([RV43`"
M&;!`6)`#.9'C`K8`>L`"%Q`#8Y!$#)`!(C"J:$H",<#_`1-?\9NNL4?P!W6@
M\;\3`YZL!@`0``%P`3\0`%A%`M97`T4G1C"`QA1`\J5VS$>@>PA/`5JEN$1:
MIBDP!!%@!F7P21_@`+V0!NME?2=@0)8>-4]`38Z&AP0``,1O!CU5]51_]9UM
M79R`7,JJRL\U``I>`60@!4U04<2X"?)6]1LYR4W>3C+P`$Z*`03P`3[!HDCP
M`#,P7#)CBGBU;%U4`!20WW35!0/0!4)``D2)&(H/"'U_?S08?W41"RD&(555
M1"9W($09&09$9P$P+W)W*0TK>!04:`B**6)<=Q,%&#</#P1C"0A<(W)3<B`B
M!BP.'6<'22MY2B%4/P8+=Q)=_RMO!6<;1"`F42`?`#X4>WL%`EH"XG/BY>;B
M*0@!)>3B$VXJ010CX0(F)QQU.%E99'!4<<)P2=).7#T!-D;4^$'@2QLR;=J@
M".*"!H$"(VP<0!"CB!0/1>H\T#$CP8D#$J(D.7`@10H3*4!L4,"$SI`.,3(<
MF,."`(0*?8X(^O.`1AT"$6X9<*2D@(@HS%Z:&+'G28<G*[J8L&%"SH$%4[8N
M,'#FB@U6+E"X@*6"`(`")3*\R$`A`8`.<#HH2#%E3YY72QZP6`$BB@034YP<
ML!8E2H,-`(*L03/D!!XH4)Q@UHRYLV<H7,*,X7&@"^83`!Y@0#*@,Y<-'31X
M\-`O1/\(('%*&.@R18B6WT*F0!F0@44'*62\*/>"XH@5#%4N&&!RXLR8+%BP
M2-&@H@A)%GI$C!"69,J""2<R`."!0,2+-!P8G)C0\V?0H:K[J'!S@D0)."$H
M$4`$-4R`2V)B%!`#$%=E,!]YY8T@Q@8_;!$>`BSTX((.03R@0AU4`,'!B!QT
MD$8:(6BPQ0H2C!#!$CWTH)H*`.!AP`0'3$$''8E=84`$J?5A!AL&&$#!&V$D
MJ8`%23;I9)(E,!3`3$D6X``&?<!00),1L``'!BB@@$,%=2@A`Q57*?!!#0.T
M68,>;[B1AA)PH%#!/F20<4,?,QQ1AP9(E,!`##+@L"$*$/S_Y$(=?6R10`8?
M$$$$`GMT"4,('?!``0`AR,(`!6;`81\$??CA!P9'^&&$`P448$:B$-1Q500K
M(+#""P7DX8@**L#`0@1[7&(``FK\P`$!'?R0P`\.!%'$6AXJT<(,,U"A!)V-
MI%B&"#:(X88K?=QP1*P$7$#!!P;4,.D&"7``1QV)^L!"JZG!8N^]^,)"PPT8
MT+"$#TLL08-0?83K;V"J'5&!'W_<Q_"I#_BPQAH``+!&'C-@8.K&'#/\AQ\5
M'(%!$'5T;"H$XA;<!P8/+)%''@X`O&]01]1L<\TFFTPS!JB6Z@<$+/OPL@,/
MI'R$N/XZD,?%#EQ;![QA%D%M$``D_^`+%3/HX(&?\$)P1`AY;#!%%!^8`6_.
M1SB@-,P^8%FPUT'$/0/)3]=M]]U/J[PRSZX0;'!1/"N\<,-!"/6PR`\$@:4?
M>N?<<<@BIVHR!(7XS??E!%>@^>:;.ZXWYS<4[K,?B%>N\M$BT]`RX!IH\/1/
M*$B-@0-[V$&$JPY(@8-(#R3::P1=),0``:(Z/JZI;]]LL^9]P.K\\\_K/8C>
M>M\@[L(<-UPS]H/\P3,$#(<;M^,<<SXZQT"#JW+WTS=.OLGF;^RUPAZSWS[-
M1UL_5!\QWASC$ABX``DD(($&A($A<)"!`JD@@RV48`(V2((!X@"$*H!O<J@R
M5>AFT#;FU?_O#TT(H0A'2,(FN$)U6&I8SZA7,/:9[&,@`\KIQJ4RQ\7O?8RK
MGKAXEC+IV6\0C@N<X8!HJH_U07.GNMP*P^4*%3Z@?T(Y0O_Z0#L0V.`.41C!
M$%9`%PI,@P212`("K$*%`'G.5)HC50M=:*H2NE&$)\R/"OVV/OMECX@>U-[Q
M8)BS&[[O?M836=^H]T,BFDR(I?HAXY"HQ"7RZP9.A&)08G2#);@%#R<8@02$
M8((#0($)$W""'"(AAQHP(&9?\`(9'`=#YA62CT:(I2QG24LCA.R1@@@7'6E6
M,)W5,(>\5!G*).=+%IY/?C8K6,WPQT(<=BR0AD->#6MX,VC6#)>'0<$`%&L6
M(Y:IP`<78,`&!H"C'9DS!0L@P0H8$`!89,<+.?,:^,)5AY'Y[6'2-*8^?;A/
M@G6L8;_L7AZ/R#-G4B]GX>KA&KMW4&=NK*'`3&0A6;C,_?6`CE(4"@1\`(,.
I$.`))4#``+@P@0F(X`1[^$$',%6'/W@`"QY`:#0K,+(9[*F7[`L$`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
